HC Wainwright&Co.:重申Inovio Pharmaceuticals(INO.US)评级,由中性调整至中性评级,目标价由3.00美元调整至3.00美元。伊诺维奥制药(INO.US)公司简介:Inovio Pharmaceuticals Inc是一家总部位于美国的生物技术公司,致力于开发基于DNA的活性免疫疗法和疫苗,以治疗和预防癌症和传染病。该公司从事基因治疗,其免疫治疗平台包括...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.